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Background
Brown et al. [1] published a favourable experience with
treatment of Staphylococcus coagulase negative (SCoN)
caused cerebrospinal fluid shunt (CSF) infections without
surgery using Rifampin (Rif). We have presented our man-
agement of CSF shunt infections, in part indicating sur-
gery is not needed for some cases. This paper is to further
describe our experience over the last 45 years.
Materials and methods
We describe a retrospective review of prospectively col-
lected data stored in two computer databases for 3,889
shunt related operations involving 1,226 patients. Infec-
tions were defined as positive cultures of the CSF or the
shunt. Antibiotic levels in the CSF and Minimal Bacterio-
cidal (MBC) levels are expressed in ug/ml. Operative pro-
cedures as part of the treatment were complete shunt
removal, ventriculostomy, antibiotics (abx) until CSF was
sterile, then replacement of the shunt ((CSR+V+abx+R),
externalization of the distal limb + abx + replacement +
(Ex+abx+R) and other procedures. Analysis was by trans-
fer to Excel files, Fisher Exact and Student t-test. A cure was
defined as 16 months without recurrent infection or a new
infection with another organism.
Results
195 infections (5.0% of shunt procedures) involved 176
patients (15.9%) of which 62 were due to SCoN organ-
isms (32%), 122 that were insensitive (61%), including
41 due to Staphylococcus aureus (21%), 13 (7%) due to
Enterococcus, 15 E. coli (8%), and 14 due to other sensi-
tive organisms (concentration of CSF antibiotic ≥10 mcg/
dl) including Streptococcus pneumoniae (5; 1:245) and
Hemophilus influenzae (9; 1:136). 28 of S Co N were
treated medically of which 22 (79%) were cured. The pro-
portion of cures was not different compared to
CSR+V+abx+R 38 of 42 (90%), Fisher Exact P = 0.5, but
better when compared to Ex+abx+R = 6/12 (50%), P =
0.01. Severity of infection, as measured by white blood
cell count in the CSF, was the same for the medically
treated (Mean 217, Range 0–939) and those with surgery
(Mean = 368, Range 1–1380), t-test P = 0.3. When poly-
morphonuclear cells alone were evaluated, the similarity
remained, P = 0.48.
Conclusion
1) Rifampin and another antibiotic, to prevent resistance,
can cure some S Co N shunt infections. 2) Patients with
CSF shunts should be immunized against H. influenzae
and S. pneumoniae, 7 valent under 2 years of age with addi-
tion of 23 valent agent for older and after age 2 years.
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